Quality of asthma treatment in children and adolescents (QUAST)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/31230
• EU PAS number:
  EUPAS29076
• Study ID:
  31230
• Official title and acronym:
  Quality of asthma treatment in children and adolescents (QUAST)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  Asthma is the most common chronic child and adolescent disease with a prevalence that has increased significantly over the past 20 years worldwide as well as the use of antiasthmatic medications. Little is known about the short and long-term therapeutic management of asthmatic children.Pharmacological treatment aims durable asthma control but despite the existence of international recommendations for the proper use of anti-asthma drugs and inhalation medical devices in this population, asthma control remains unacceptable for at least one-third of asthmatic children and adolescents.The aim of this study is to assess the prescribing patterns of antiasthma drugs and inhalation medical devices, oral corticosteroids and antibiotics in asthmatic children in primary care in France in order to identify deviations from recommendations.
• Study status:
  Ongoing

Research institution and networks

Institutions

Assistance Publique - Hôpitaux de Paris (AP-HP)

France

Study timelines

Date when funding contract was signed

Actual: 02/11/2016

Study start date

Planned: 01/01/2018

Actual: 11/05/2018

Date of final study report

Planned: 31/12/2020

Sources of funding

Other

More details on funding

ANSM

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable